2-(2-溴噻唑-4-基)乙腈 | 1254558-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(2-溴噻唑-4-基)乙腈
• 英文名称: 2-(2-bromothiazol-4-yl)acetonitrile
• 英文别名: 2-(2-bromo-1,3-thiazol-4-yl)acetonitrile
• CAS: 1254558-78-5
• 化学式: C₅H₃BrN₂S
• 分子量: 203.062
• InChiKey: SDZVWJBEDJCDLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  304.7±17.0 °C(Predicted)
• 密度：
  1.773±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  64.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-溴噻唑-4-基)乙腈 在 N-溴代丁二酰亚胺(NBS) 、 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 1-(5-bromo-2-((4-methoxybenzyl)(methyl)amino)thiazol-4-yl)cyclopropane-1-carbonitrile
  参考文献：
  名称：

  [EN] SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES
  [FR] DÉRIVÉS DE 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE SUBSTITUÉS ET UTILISATIONS ASSOCIÉES

  摘要：

  The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  公开号：

  WO2023240134A1
• 作为产物：
  描述：

  potassium cyanide 、 4-(chloromethyl)thiazol-2-amine hydrochloride 在 硫酸 、 sodium nitrite 、 氢溴酸 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.33h， 以31%的产率得到2-(2-溴噻唑-4-基)乙腈
  参考文献：
  名称：

  Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides

  摘要：

  The parasitic trypanosomes Trypanosoma brucei and T. cruzi are responsible for significant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease. Drugs currently available to treat these neglected diseases leave much to be desired. Herein we report optimization of a novel class of N-(2-(2-phenylthiazol-4-yl)ethyl)amides, carbamates, and ureas, which rapidly, selectively, and potently kill both species of trypanosome. The mode of action of these compounds is unknown but does not involve CYP51 inhibition. They do, however, exhibit clear structure activity relationships, consistent across both trypanosome species. Favorable physicochemical parameters place the best compounds in CNS drug-like chemical space but, as a class, they exhibit poor metabolic stability. One of the best compounds (64a) cleared all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved in one mouse. This family of compounds thus shows significant promise for trypanosomiasis drug discovery.

  DOI：

  10.1021/acs.jmedchem.6b00442

文献信息

• [EN] PYRAZOLOPYRIDINES<br/>[FR] PYRAZOLOPYRIDINES
  申请人：VERTEX PHARMA

  公开号：WO2010129668A1

  公开（公告）日：2010-11-11

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及作为蛋白激酶抑制剂的化合物。该发明还提供包含所述化合物的药学上可接受的组合物，并提供使用这些组合物治疗各种疾病、症状或紊乱的方法。该发明还提供制备本发明化合物的方法。
• PYRAZOLOPYRIDINES
  申请人：Jimenez Juan-Miguel

  公开号：US20120178778A1

  公开（公告）日：2012-07-12

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及一种作为蛋白激酶抑制剂有用的化合物。本发明还提供了包括该化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病、病况或障碍的方法。本发明还提供了制备本发明化合物的方法。
• Pyrazolopyridines
  申请人：Jimenez Juan-Miguel

  公开号：US08541445B2

  公开（公告）日：2013-09-24

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及用作蛋白激酶抑制剂的化合物。本发明还提供了包含所述化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病、病况或障碍的方法。本发明还提供了制备本发明化合物的方法。
• Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides
  作者：Stephanie Russell、Raphaël Rahmani、Amy J. Jones、Harriet L. Newson、Kevin Neilde、Ignacio Cotillo、Marzieh Rahmani Khajouei、Lori Ferrins、Sana Qureishi、Nghi Nguyen、Maria S. Martinez-Martinez、Donald F. Weaver、Marcel Kaiser、Jennifer Riley、John Thomas、Manu De Rycker、Kevin D. Read、Gavin R. Flematti、Eileen Ryan、Scott Tanghe、Ana Rodriguez、Susan A. Charman、Albane Kessler、Vicky M. Avery、Jonathan B. Baell、Matthew J. Piggott

  DOI：10.1021/acs.jmedchem.6b00442

  日期：2016.11.10

  The parasitic trypanosomes Trypanosoma brucei and T. cruzi are responsible for significant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease. Drugs currently available to treat these neglected diseases leave much to be desired. Herein we report optimization of a novel class of N-(2-(2-phenylthiazol-4-yl)ethyl)amides, carbamates, and ureas, which rapidly, selectively, and potently kill both species of trypanosome. The mode of action of these compounds is unknown but does not involve CYP51 inhibition. They do, however, exhibit clear structure activity relationships, consistent across both trypanosome species. Favorable physicochemical parameters place the best compounds in CNS drug-like chemical space but, as a class, they exhibit poor metabolic stability. One of the best compounds (64a) cleared all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved in one mouse. This family of compounds thus shows significant promise for trypanosomiasis drug discovery.
• [EN] SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES<br/>[FR] DÉRIVÉS DE 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE SUBSTITUÉS ET UTILISATIONS ASSOCIÉES
  申请人：[en]NODTHERA LIMITED

  公开号：WO2023240134A1

  公开（公告）日：2023-12-14

  The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.